The FDA on February 25, 2020 approved NERLYNX® in combination with XELODA® (Capecitabine) for adult patients with advanced or metastatic HER2-positive Breast Cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting. NERLYNX® is a product of Puma Biotechnology, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
